Nuwellis to introduce 24-hour circuit for Aquadex therapy this fall.

Nuwellis, a fluid management company, plans to introduce a new 24-hour circuit for Aquadex therapy in the US this fall. This complements their existing 72-hour option and aims to match supply to setting while maintaining a consistent therapy experience. The 24-hour circuit supports outpatient programs by aligning with single-visit workflows, easing scheduling, and increasing capacity. This helps hospitals deliver predictable, scheduled care for patients and scale their clinics.

Minneapolis, Sept. 02, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a fluid management company, has announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. This addition complements the company’s existing 72-hour option, which is commonly used for multi-day therapy or inpatient care. The new circuit is designed to support single-day outpatient sessions, aligning with hospitals' growing outpatient Aquadex programs.

The 24-hour circuit aims to deliver predictable, scheduled care for patients who need fluid removal without a hospital admission. It supports outpatient programs by aligning with single-visit workflows, easing scheduling, and increasing capacity. For providers and administrators, the circuit offers a reliable pathway to run more efficient clinics and scale capacity. According to John Erb, Chairman of the Board and Chief Executive Officer of Nuwellis, “Hospital-based outpatient Aquadex therapy is growing as a reliable option for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model with a straightforward single-visit pathway.”

Nuwellis provides program resources for hospital-based outpatient sites, including patient identification, implementation guidance, and staff education, to help teams add or expand Aquadex therapy in ambulatory settings. The Aquadex SmartFlow® system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

This new development is part of Nuwellis’ ongoing strategy to meet the growing demand for outpatient Aquadex therapy. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy, aiming to transform the lives of patients suffering from fluid overload through science, collaboration, and innovation.

For more information, visit [Nuwellis' website](https://www.nuwellis.com).

References:
[1] https://www.stocktitan.net/news/NUWE/nuwellis-introduces-new-24-hour-aquadex-tm-circuit-to-support-zg4gkl66jp3t.html